Herpes zoster and postherpetic neuralgia in Catalonia (Spain)

Salleras, L.; Salleras, M.; Salvador, Pablo; Soldevila, Núria; Prat, A.; Garrido, P.; Domı́nguez, Àngela

doi:10.4161/hv.34421

Cited by 9 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Spain, data on the impact of HZ and complications such as PHN on HRQL and healthcare costs are limited, and studies are mainly retrospective in approach [16,[20][21][22][23]. As such additional data are of value to provide a better understanding of the impact of these aspects in Spain.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older: A Prospective Cohort Study

Díez‐Domingo

Curran

Cambronero³

et al. 2021

Adv Ther

View full text Add to dashboard Cite

Introduction:The economic burden of herpes zoster (HZ), including its most common complication, postherpetic neuralgia (PHN), and its impact on health-related quality of life (HRQL) is not well described in Spain. The aim of this study was to estimate HZ-related healthcare costs and impact on HRQL in Spanish adults aged 50 years or older. Methods: A prospective, observational study was performed with patients with HZ recruited through four general practitioner networks in Spain (NCT01521286). HRQL data were collected using the EuroQoL-5 Dimension (EQ-5D) questionnaire; HZ-related pain and associated interference with activities of daily living (ADL) were assessed using the Zoster Brief Pain Inventory (ZBPI) questionnaire at days 0 (HZ rash onset), 15, 30, 60, and 90; patients with PHN were assessed up until day 270. Medical resource utilization was recorded throughout study follow-up. Work loss for patients/caregivers was also assessed. Costs were calculated from both the payer and societal perspectives. Results: A total of 545 patients with Hz were included, of whom 25 developed PHN. During days 0-30 post HZ diagnosis, the mean EQ-5D utility score was 0.738, equating to a utility loss of 0.138. Sleep was the ADL most affected component. The mean costs for HZ in the overall cohort were €240 and €296 from the payer/societal perspective, respectively; €187/ €242 for patients with HZ without any HZ-related complications; and €571/€712 for patients who developed PHN. The majority of costs were incurred during days 0-30. Conclusions: In Spain, HZ and HZ-related complications such as PHN reduce patient HRQL and increase the economic burden for both payers and society in general. Trail Registration: ClinicalTrials.gov identifier NCT01521286.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Similar to other countries, higher incidence is reported in women and in the immunocompromised, and in patients with specific comorbidities such as COPD [ 16 – 18 ]. PHN is estimated to develop in between 12% and 16% of patients [ 19 , 20 ].…”

Section: Introductionmentioning

confidence: 99%

Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older: A Prospective Cohort Study

Díez‐Domingo

Curran

Cambronero³

et al. 2021

Adv Ther

View full text Add to dashboard Cite

show abstract

“…El 50% de los individuos que llegan a los 85 años de edad sin haber padecido el herpes zóster, lo padecerán durante los años que sobrevivan a partir de esta edad 138 . La complicación más frecuente es la neuralgia posherpética, un dolor de origen neuropático que aparece o persiste más allá de los 3 meses después de la curación del exantema vesicular dermatómico 139 . La desarrollan alrededor del 15% de los casos ocurridos en personas de 50 o más años, aunque llega al 17,5% en los mayores de 70 años 138 .…”

Section: Carga De La Enfermedadunclassified

“…La desarrollan alrededor del 15% de los casos ocurridos en personas de 50 o más años, aunque llega al 17,5% en los mayores de 70 años 138 . El dolor ocasionado por esta complicación puede llegar a ser prolongado y debilitante reduciendo la calidad de vida del paciente 139 . El tratamiento con aciclovir reduce la gravedad y la duración de herpes zóster, pero no es eficaz en la prevención de la neuralgia posherpética 6,138,139 .…”

Section: Carga De La Enfermedadunclassified

See 1 more Smart Citation

Vacunas frente al virus de la varicela zóster

Salleras

Soldevila

et al. 2015

Enfermedades Infecciosas y Microbiología Clínica

Self Cite

View full text Add to dashboard Cite

Decline in hospitalization rates for herpes zoster in Italy (2003–2018): reduction in the burden of disease or changing of hospitalization criteria?

et al. 2022

View full text Add to dashboard Cite

Background Herpes Zoster (HZ) is a very demanding disease caused by the reactivation of latent Varicella Zoster Virus. The main aim of this study was to estimate the burden of the HZ hospitalizations in Italy from 2003 to 2018 evaluating temporal trends. Methods Retrospective population-based study analyzing Hospital Discharge Records. Hospitalization records reporting the ICD-9 CM 053.X code in the principal diagnosis or in any of the five secondary diagnoses were considered as cases. Trends of hospitalization rates have been evaluated by Joinpoint analyses. Results Overall, 99,036 patients were hospitalized with HZ in the 16-year period of the study, and 83,720 (84.5%) of these patients were over 50 years. Hospitalization rate was 10.4 per 100,000 persons/year with a significant decreasing trend from 13.9 in 2003-2006 to 7.8 in 2015-2018 (p < 0.001). Hospitalization rates showed a 20-fold higher risk among subjects aged over 80 years and 11-fold higher risk among 70-79-year-old subjects with respect to those aged less than 50 years. Over time, a statistically significant increase was observed for the case fatality rate (from 1.2 to 1.7%; p < 0.001) and the median length of stay (from 7 to 8 days; p < 0.001). Conclusions Zoster is a disease that causes hospitalization as relatively frequent complication and the observed reduced trend over time could be due to a restriction in hospitalization criteria instead of a reduced burden of disease. The decreasing trend should be carefully interpreted, since it could have an impact on promoting herpes zoster vaccination.

show abstract

Herpes zoster and postherpetic neuralgia in Catalonia (Spain)

Cited by 9 publications

References 31 publications

Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older: A Prospective Cohort Study

Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older: A Prospective Cohort Study

Vacunas frente al virus de la varicela zóster

Decline in hospitalization rates for herpes zoster in Italy (2003–2018): reduction in the burden of disease or changing of hospitalization criteria?

Contact Info

Product

Resources

About